

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Suketu P. Sanghvi et al.  
Serial No.: 10/821,811  
Confirmation No.: 9061  
Filed: April 8, 2004  
For: PHARMACEUTICAL FORMULATION  
Examiner: D. A. Jagoe  
Art Unit: 1614

**Certificate of Electronic Filing Under 37 CFR 1.8**  
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: July 11, 2008

Signature:  (Judy Daley)

**RESPONSE TO RESTRICTION REQUIREMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed January 11, 2008, Applicant hereby provisionally elects Group VI (Claims 231-232 and 235-246) for continued examination.

Applicant elects the patentably distinct species of chelating agent. To further aid the Examiner in searching Applicants provide the election of the following chelating agent compound: edetate calcium disodium.

Applicant's election is made without traverse. As noted by the Examiner, upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which are dependent from or otherwise include all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

In addition, Applicants provide amendments to the claims, that begin on page 2.

Remarks begin on page 24.

Conclusion begins on page 25.